Dr. Martin Kaiser on Myeloma Treatment in the UK and the Study of Myeloma Genomics

Dr. Martin Kaiser on Myeloma Treatment in the UK and the Study of Myeloma Genomics
Event Description
Martin Kaiser, MD Institute of Cancer Research Interview Date: February 5, 2018
Summary Martin Kaiser, MD of the Institute of Cancer Research in the United Kingdom joins Myeloma Crowd Radio at ASH 2017 to discuss myeloma care in the United Kingdom and how the aggregation of myeloma genomic data from over 4,000 myeloma patients has helped advance myeloma research. He shares a new study for high-risk newly diagnosed patients in the UK at over 20 hospitals and discusses two genomic tests that are being run on these patients to better understand disease progression when it happens early for these patients who are more likely to relapse early.
Thanks to our episode sponsor, SparkCures
Schedule & Agenda
Speakers & Moderators

Martin Kaiser, MD, RWTH, is a Clinician Scientist and Honorary Consultant Haematologist at The Institute of Cancer Research (ICR) and The Royal Marsden NHS Foundation Trust in London, United Kingdom. In 2018, he became Team Leader of the Myeloma Molecular Therapy Group at the ICR. Dr. Kaiser’s main research interest is the molecular characterization of multiple myeloma with the aim of designing gentler therapies tailored to patients’ needs. His team is working on state-of-the-art genetic profiling to gain insight into the evolution of myeloma and the development of treatment resistance. He is the chief investigator of the national OPTIMUM trial, which offers tailored therapy for patients with molecular high-risk disease. He is active member of the UK NCRI group, the UK Myeloma Research Alliance (UKMRA) network and the UK Myeloma Forum and serves as principal or co-investigator for several national and international myeloma trials. Prior to moving to London, Dr. Kaiser specialized in hematology-oncology at Charité University Medicine in Berlin, Germany. He earned his medical degree at the University of Aachen, Germany, where he also obtained an MD in Pathology for research on multiple myeloma microenvironment interactions.

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Have Any Questions?
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
Get In Touch With Us
1-800-709-1113
Support@healthtree.org






Get the Latest Multiple Myeloma Updates, Delivered to You.
By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.